RG
GTHX

Redmile Group’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

Redmile Group’s Portfolio GTHX Stock Details GTHX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-613,734
Closed -$16.2M – 76
2019
Q4 		$16.2M Buy
613,734
+222,800
+57% +$5.21M 0.39% 53
2019
Q3 		$8.9M Buy
390,934
+98,200
+34% +$3.1M 0.3% 54
2019
Q2 		$8.97M Buy
+292,734
New +$6.16M 0.25% 58

Other funds holding GTHX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Redmile Group's GTHX Position: Q1 2020 in Review

Redmile Group sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q1 2020, closing a stake of 613,734 shares — an estimated $16.2M sold.

Redmile Group first reported a position in GTHX in Q2 2019 and held it in 3 quarters. The position peaked at $16.2M in Q4 2019. 100 funds tracked by Wall St. Rank hold GTHX as of Q1 2020.

  • Redmile Group reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
  • Redmile Group sold 613,734 G1 Therapeutics, Inc. Common Stock shares in Q1 2020, an estimated $16.2M.
  • Redmile Group first reported a position in G1 Therapeutics, Inc. Common Stock in Q2 2019 and held it in 3 quarters.
  • Redmile Group's G1 Therapeutics, Inc. Common Stock position peaked at $16.2M in Q4 2019.
  • 100 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q1 2020.

Based on Redmile Group's 13F filing for Q1 2020, filed 15 May 2020.